Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA

BACKGROUND: Alectinib is an approved treatment for anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small-cell lung cancer. Despite positive supporting clinical data, there is a lack of real-world information on the usage and patient outcomes of those treated with alectinib post-...

Descripción completa

Detalles Bibliográficos
Autores principales: DiBonaventura, Marco D, Wong, William, Shah-Manek, Bijal, Schulz, Mathias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744742/
https://www.ncbi.nlm.nih.gov/pubmed/29317835
http://dx.doi.org/10.2147/OTT.S144960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744742/
https://www.ncbi.nlm.nih.gov/pubmed/29317835
http://dx.doi.org/10.2147/OTT.S144960

Ejemplares similares